GLP-1 drugs like Ozempic and Wegovy have revolutionized the management of diabetes and obesity. Millions of Americans are experimenting with them. Celebrities like Oprah are sharing their experiences. Duke Sanford School of Public Policy faculty member Jonathan Zhang is an economist who works on health policy, health economics and public finance. His research shows that GLP-1 drugs live up to their promise in everyday medical care. But the study also finds that, at least in the short run, they do not reduce overall health care spending.